anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Malathion
Trial phase: Not Applicable
ATC code: P03AX03
SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 241
Group description: Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
Eligibility criteria:
Inclusion Criteria:

Female partners had complete or partial tubal patency
Male partners with anti-sperm antibodies
Male partners with sperm count > 35 million/ml.

Exclusion Criteria:

Female partners with polycystic ovary
Female partners with endometriosis
Female partners with abnormal profile of reproductive hormones
Female partners with abnormal profile of thyroid hormones
Male partners with seminal fluid infections (e.g. leukospermia)
Male partners with abnormal profile of reproductive hormones
Male partners with abnormal profile of thyroid hormones
Intervention: Malathion
Trial phase: Not Applicable
ATC code: P03AX03
SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 241
Group description: Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
Eligibility criteria:
Inclusion Criteria:

Female partners had complete or partial tubal patency
Male partners with anti-sperm antibodies
Male partners with sperm count > 35 million/ml.

Exclusion Criteria:

Female partners with polycystic ovary
Female partners with endometriosis
Female partners with abnormal profile of reproductive hormones
Female partners with abnormal profile of thyroid hormones
Male partners with seminal fluid infections (e.g. leukospermia)
Male partners with abnormal profile of reproductive hormones
Male partners with abnormal profile of thyroid hormones
Intervention: Fulvestrant
Trial phase: Phase 1
ATC code: L02BA03
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])c3ccc(O)cc3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: 750 mg injection in 3 divided doses

Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
Eligibility criteria:
Inclusion Criteria:

Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the study treatment regimen and follow-up, must be obtained and documented according to the local regulatory requirements
Adult women greater than 18 years old
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer

Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater
Hormone receptor positive as defined as ≥ 10% positive stained cells
HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio <= 2.0 status])
Tumor size at least 5 mm with planned primary surgery at Mount Sinai
A negative urine dipstick pregnancy test

Exclusion Criteria:

Estrogen receptor negative invasive breast carcinoma as defined as less than 10% stained cells
Prior antiestrogen therapy
Tumor size less than 5 mm
Prior diagnosis of thrombosis or known hypercoagulable state
Known history of bleeding diathesis
Known liver disease
Prior treatment with neoadjuvant therapy
Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema).
Current severe or uncontrolled systemic disease
Pregnancy or lactation period. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices) during study treatment.
Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.
Intervention: Tamoxifen
Trial phase: Phase 1
ATC code: L02BA01
SMILES: CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: 20mg orally

Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day
Eligibility criteria:
Inclusion Criteria:

Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the study treatment regimen and follow-up, must be obtained and documented according to the local regulatory requirements
Adult women greater than 18 years old
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer

Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater
Hormone receptor positive as defined as ≥ 10% positive stained cells
HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio <= 2.0 status])
Tumor size at least 5 mm with planned primary surgery at Mount Sinai
A negative urine dipstick pregnancy test

Exclusion Criteria:

Estrogen receptor negative invasive breast carcinoma as defined as less than 10% stained cells
Prior antiestrogen therapy
Tumor size less than 5 mm
Prior diagnosis of thrombosis or known hypercoagulable state
Known history of bleeding diathesis
Known liver disease
Prior treatment with neoadjuvant therapy
Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema).
Current severe or uncontrolled systemic disease
Pregnancy or lactation period. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices) during study treatment.
Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 300
Group description: Patients in the treatment arm will be given propofol only when having a colonoscopy.

Propofol: The intervention is to use propofol as anesthesia during a colonoscopy.
Eligibility criteria:
Inclusion Criteria:

- Patients having an outpatient colonoscopy

Exclusion Criteria:

- High risk patients (ASA IV & V) who are not candidates for colonoscopy in an outpatient center will be excluded.
Intervention: Midazolam
Trial phase: Phase 4
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 300
Group description: Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.

Fentanyl Plus Midazolam: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
Eligibility criteria:
Inclusion Criteria:

- Patients having an outpatient colonoscopy

Exclusion Criteria:

- High risk patients (ASA IV & V) who are not candidates for colonoscopy in an outpatient center will be excluded.
Intervention: Ethanol
Trial phase: Phase 2
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 68
Group description: Lotion

IDP-123 Lotion: Lotion
Eligibility criteria:
Key Inclusion Criteria:

Male or female at least 12 years of age and older.
Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).
Women of childbearing potential and females that are pre-menses must be willing to practice effective contraception for the duration of the study. (Effective contraception is defined as stabilized on oral contraceptive for at least 3 months, IUD, condom with spermicidal, diaphragm with spermicidal, implant, Nuvaring, injection, transdermal patch or abstinence.) Females on birth control pills must have taken the same type pill for at least three months prior to entering the study and must not change type during the study. Those who have used birth control pills in the past must have discontinued usage at least three months prior to the start of the study. Women who use birth control for acne control only should be excluded.
Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits.

Key Exclusion Criteria:

Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;
Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis, dermatitis, eczema.
Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
Subjects with a facial beard or mustache that could interfere with the study assessments.
Evidence or history of cosmetic-related acne.
Subject has a history of experiencing significant burning or stinging when applying any facial treatment (eg, make-up, soap, masks, washes, sunscreens, etc) to their face.
Intervention: Tazarotene
Trial phase: Phase 2
ATC code: D05AX05 | D05AX55
SMILES: CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 71
Group description: Cream

Tazorac Cream: Cream
Eligibility criteria:
Key Inclusion Criteria:

Male or female at least 12 years of age and older.
Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).
Women of childbearing potential and females that are pre-menses must be willing to practice effective contraception for the duration of the study. (Effective contraception is defined as stabilized on oral contraceptive for at least 3 months, IUD, condom with spermicidal, diaphragm with spermicidal, implant, Nuvaring, injection, transdermal patch or abstinence.) Females on birth control pills must have taken the same type pill for at least three months prior to entering the study and must not change type during the study. Those who have used birth control pills in the past must have discontinued usage at least three months prior to the start of the study. Women who use birth control for acne control only should be excluded.
Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits.

Key Exclusion Criteria:

Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;
Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis, dermatitis, eczema.
Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
Subjects with a facial beard or mustache that could interfere with the study assessments.
Evidence or history of cosmetic-related acne.
Subject has a history of experiencing significant burning or stinging when applying any facial treatment (eg, make-up, soap, masks, washes, sunscreens, etc) to their face.
Intervention: Phenytoin
Trial phase: Phase 2
ATC code: N03AB02 | N03AB52
SMILES: O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 21
Group description: patients received phenytoin 100mg three time daily up to 3 months

Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
Eligibility criteria:
Inclusion Criteria:

isolated, unilateral, first acute optic neuritis (confirmed by neuroophthalmologist)
willing to receive a steroidal regimen
no pathologic finding in first oct
no pathology and history of optic neuritis in contralateral eye
<14 days since onset visual loss

Exclusion Criteria:

Contraindication or known allergy to Phenytoin
Use of a calcium channel or sodium channel blocker in the past 2 months
Corticosteroid use in the past 2 months
Pregnancy
Significant cardiac, renal or liver abnormalities
Prior clinical episode of optic neuritis in either eye
Bilateral acute optic neuritis
Known ocular or neurological conditions or abnormalities other than refractive error that impair visual function
Refractive error of greater than +5 or -5 diopters
Any condition that may interfere with performance of Optical Coherence Tomography (OCT): corneal, lens or fundoscopic abnormality, a co-morbid ocular condition not related to optic neuritis as detected on the OCT reading
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Male
Age groups: Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Administration via nasal spray

Syntocinon (Oxytocin): Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of Autism Spectrum Disorder, Asperger Syndrome or Autism
Male
Age between 18 and 40 years old

Exclusion Criteria:

Associated neuro(psycho)logical disorder (i.e. epilepsy, concussion, stroke)
Eye sight worse than + or - 7
Genetic syndrome
Color blindness
Any contraindication to neuroimaging research as assessed with the MRI screening list:

MRI contraindications:

pacemaker, implanted defibrillator, ear implant / a cochlear implant, insulin or implanted pump, a neurostimulator or VP shunt, any metallic object in the eyes (metallic fragments)
Intervention: OXYTOCIN
Trial phase: Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 66
Group description: Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.

Oxytocin
Eligibility criteria:
Inclusion Criteria:

18-65 years of age
both partners are willing to participate, and
at least one partner has engaged in hazardous drinking (i.e. 4 or more drinks for women, 6 or more for men) or illicit drug use during the past 60 days

Exclusion Criteria:

pregnancy for women
current psychotic or bipolar disorders
active suicidal or homicidal ideation and intent
subjects who would present a serious suicide risk, such as those with severe depression, or who are likely to require hospitalization during the course of the study
severe, unilateral intimate partner violence in the past year
BMI greater than 39.
Intervention: Apixaban
Trial phase: Phase 4
ATC code: B01AF02
SMILES: COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients; >= 80 years old or dry body weight/hemodialysis target body weight <= 60 kg)

apixaban: oral anticoagulant
Eligibility criteria:
Inclusion Criteria:

Males and females, age at least 18 years, or the local age of consent, whichever is greater.
Patients with AF defined as AF on ECG at enrollment or two or more reports of AF from separate monitoring events at least 2 weeks apart (report of ECG, Holter monitor, event monitor or implantable loop recorder).
CHA2DS2-VASc score of ≥ 2.
End-stage renal disease treated with hemodialysis for ≥ 3 months.
Considered by the treating physician(s) to be candidate for oral anticoagulation.
If of childbearing potential, be willing to avoid pregnancy during the study.

Exclusion Criteria:

Not considered by the treating physician(s) to be candidates for oral anticoagulation (for example, hemoglobin < 8.5g/dL, history of intracranial hemorrhage, active bleeding, recent gastrointestinal bleed or retroperitoneal bleed, severe hepatic impairment, or anaphylactic reaction to apixaban)
Moderate or severe mitral stenosis
Conditions other than AF that require anticoagulation such as mechanical prosthetic valve, deep venous thrombosis, or pulmonary embolism
Need for aspirin at a dose > 81 mg a day or need for P2Y12 antagonist therapy (for example clopidogrel, prasugrel, or ticagrelor)
Life expectancy < 3 months
Anticipated kidney transplant within the next 3 months
Prisoners or others who are involuntarily incarcerated or detained
Pregnant, breastfeeding, or considering pregnancy.
Participation in a clinical trial of an experimental treatment within the past 30 days
Intervention: Warfarin
Trial phase: Phase 4
ATC code: B01AA03
SMILES: CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 68
Group description: warfarin daily dose adjusted to target International Normalized Ratio (INR) of 2-3

warfarin: oral anticoagulant
Eligibility criteria:
Inclusion Criteria:

Males and females, age at least 18 years, or the local age of consent, whichever is greater.
Patients with AF defined as AF on ECG at enrollment or two or more reports of AF from separate monitoring events at least 2 weeks apart (report of ECG, Holter monitor, event monitor or implantable loop recorder).
CHA2DS2-VASc score of ≥ 2.
End-stage renal disease treated with hemodialysis for ≥ 3 months.
Considered by the treating physician(s) to be candidate for oral anticoagulation.
If of childbearing potential, be willing to avoid pregnancy during the study.

Exclusion Criteria:

Not considered by the treating physician(s) to be candidates for oral anticoagulation (for example, hemoglobin < 8.5g/dL, history of intracranial hemorrhage, active bleeding, recent gastrointestinal bleed or retroperitoneal bleed, severe hepatic impairment, or anaphylactic reaction to apixaban)
Moderate or severe mitral stenosis
Conditions other than AF that require anticoagulation such as mechanical prosthetic valve, deep venous thrombosis, or pulmonary embolism
Need for aspirin at a dose > 81 mg a day or need for P2Y12 antagonist therapy (for example clopidogrel, prasugrel, or ticagrelor)
Life expectancy < 3 months
Anticipated kidney transplant within the next 3 months
Prisoners or others who are involuntarily incarcerated or detained
Pregnant, breastfeeding, or considering pregnancy.
Participation in a clinical trial of an experimental treatment within the past 30 days
Intervention: Metronidazole
Trial phase: Phase 4
ATC code: A01AB17 | A02BD01 | A02BD02 | A02BD03 | A02BD08 | A02BD11 | A02BD13 | A02BD15 | D06BX01 | G01AF01 | G01AF20 | J01RA03 | J01RA04 | J01RA10 | J01RA14 | J01XD01 | P01AB01 | P01AB51 | P01AB52
SMILES: Cc1ncc([N+](=O)[O-])n1CCO
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 7
Group description: Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.

Metronidazole: P/r suppositories
Eligibility criteria:
Inclusion Criteria:

clinical symptoms could be explained by giardiasis AND
fecal samples will test positive for the presence of G.lamblia in Uusimaa laboratory (HUSLAB)

Exclusion Criteria:

age <6 mo or >10 years
weight <9.5 kg
the absence of symptoms
co-infection with another pathogen, which may cause giardiasis-like symptoms
Intervention: Tinidazole
Trial phase: Phase 4
ATC code: A02BD09 | G01AF20 | G01AF21 | J01RA11 | J01RA13 | J01XD02 | P01AB02
SMILES: CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 1
Group description: Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose

Tinidazole: P/o tablets
Eligibility criteria:
Inclusion Criteria:

clinical symptoms could be explained by giardiasis AND
fecal samples will test positive for the presence of G.lamblia in Uusimaa laboratory (HUSLAB)

Exclusion Criteria:

age <6 mo or >10 years
weight <9.5 kg
the absence of symptoms
co-infection with another pathogen, which may cause giardiasis-like symptoms